11/12
07:23 am
rptx
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib [Yahoo! Finance]
Medium
Report
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib [Yahoo! Finance]
11/12
07:05 am
rptx
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Medium
Report
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
11/8
11:37 am
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/7
07:18 am
rptx
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/7
07:05 am
rptx
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Low
Report
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
10/24
03:27 pm
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/24
06:15 am
rptx
Repare Therapeutics' individualised anaemia management trial shows promise [Yahoo! Finance]
Low
Report
Repare Therapeutics' individualised anaemia management trial shows promise [Yahoo! Finance]
10/23
06:10 am
rptx
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
Low
Report
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
10/23
06:05 am
rptx
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Low
Report
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
10/14
05:00 pm
rptx
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Financial Post (Toronto, Ontario, Canada)]
10/14
07:11 am
rptx
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Yahoo! Finance]
Medium
Report
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Yahoo! Finance]
10/14
07:05 am
rptx
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor
Medium
Report
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor
9/30
04:12 pm
rptx
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting [Yahoo! Finance]
High
Report
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting [Yahoo! Finance]
9/30
04:05 pm
rptx
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Low
Report
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
9/27
10:38 am
rptx
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company [Yahoo! Finance]
Low
Report
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company [Yahoo! Finance]
9/23
08:17 am
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/23
07:12 am
rptx
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers [Yahoo! Finance]
Medium
Report
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers [Yahoo! Finance]
9/23
07:05 am
rptx
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Medium
Report
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
9/13
07:00 am
rptx
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
High
Report
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
9/4
08:06 am
rptx
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
8/30
06:26 pm
rptx
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data [Seeking Alpha]
Low
Report
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data [Seeking Alpha]
8/29
09:48 am
rptx
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets [Yahoo! Finance]
Low
Report
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets [Yahoo! Finance]
8/29
05:31 am
rptx
Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic Landscape [Yahoo! Finance]
Low
Report
Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic Landscape [Yahoo! Finance]
8/28
04:05 pm
rptx
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Low
Report
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
8/27
07:05 am
rptx
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Medium
Report
Repare Therapeutics to Participate in Two Upcoming Investor Conferences